98%
921
2 minutes
20
Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the advantages of leveraging the tumor suppressive activity of microRNA (miRNA/miR), clinical translation remains limited due to incomplete understanding of their context-specific gene targets. Here, we employed a biotinylated-miRNA pull-down approach to systematically identify direct targets of miR-497-5p, an miRNA markedly downregulated in DPM. Surprisingly, multiple identified targets were not predicted by algorithms. Using patient samples, cell lines, murine xenograft models, and our localized nanoparticle miRNA delivery platform, we validated miR-497-5p anti-tumor mechanisms, which consisted of pro-apoptotic and anti-cell-cycle effects. Of multiple additional gene associations to DPM biology, we identified a synthetic lethal-type interaction whereby miR-497-5p co-inhibits PKMYT1 and WEE1 cell-cycle kinases (G2/M regulators). They were significantly overexpressed (poorly prognostic) in DPM, suggesting an efficacious treatment regimen to be explored. We demonstrate the utility of experimentally deriving the miR-497-5p targetome, explaining its pathophysiological role in DPM and why it is a rational therapeutic for further development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266497 | PMC |
http://dx.doi.org/10.1016/j.omtn.2025.102610 | DOI Listing |
Mol Ther Nucleic Acids
September 2025
Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the advantages of leveraging the tumor suppressive activity of microRNA (miRNA/miR), clinical translation remains limited due to incomplete understanding of their context-specific gene targets. Here, we employed a biotinylated-miRNA pull-down approach to systematically identify direct targets of miR-497-5p, an miRNA markedly downregulated in DPM.
View Article and Find Full Text PDFEur J Pharmacol
June 2025
School of Pharmacy, Bengbu Medical University, Bengbu, China; Anhui Engineering Technology Research Center of Biochemical Pharmaceutical, Bengbu, China. Electronic address:
AML is the most common and lethal type of leukemia. The mutant of FLT3 kinase is the most common mutation in AML. Based on the structure analysis and deuteration modification of the cmpd 18 (CHMFL-FLT3-122), a potent and orally available FLT3 Kinase inhibitor, cmpd D6 (FH-001) was found, which demonstrated a remarkable inhibitory effect on the proliferation of FLT3 - ITD positive AML cancer cell lines.
View Article and Find Full Text PDFBiochem Biophys Rep
March 2025
Post-Graduate Program in Pharmaceutical Sciences (PPGCF), Federal University of Ceará (UFC), Fortaleza, CE, Brazil.
Melanoma is the most aggressive and lethal type of skin cancer, responsible for approximately 60,000 deaths annually. The main strategy for treating melanoma is surgery to completely remove the lesion and its margins. However, for more advanced cases with a high recurrence rate, the preferred approach is to combine chemotherapy with immunotherapy treatments.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
February 2025
Hematology and Oncology research center, Tabriz university of medical sciences, Tabriz, Iran.
Background: Lung cancer, a lethal type of malignancy in the world, has different pathological subcategories, among which NSCLC is the most common form. The complex pathogenesis of this disease has caused its treatment in advanced stages to be accompanied by many problems. Recently, the genes involved in metabolism, especially those coding for membrane transporter proteins (the solute carrier) have received attention in cancer studies.
View Article and Find Full Text PDFJ Mater Chem B
February 2024
Department of Pharmaceutical Chemistry, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424001, India.
Glioblastoma (GBM) is a highly aggressive and lethal type of brain tumor with complex and diverse molecular signaling pathways involved that are in its development and progression. Despite numerous attempts to develop effective treatments, the survival rate remains low. Therefore, understanding the molecular mechanisms of these pathways can aid in the development of targeted therapies for the treatment of glioblastoma.
View Article and Find Full Text PDF